pyrroles has been researched along with Nasopharyngeal Carcinoma in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, XT; Guo, KY; He, YJ; Huang, YX; Li, YH; Song, CY; Wu, BY | 1 |
| Cao, K; Chen, Q; Guo, L; Guo, S; Guo, X; Guo, Y; Han, F; He, Q; Li, Y; Liang, Y; Liu, H; Liu, L; Liu, N; Ma, J; Mai, H; Mo, H; Mo, Y; Sun, R; Sun, X; Tang, L; Tang, Q; Wang, J; Wang, P; Xie, C; Yang, X; Ye, Y; Zeng, M; Zhang, L | 1 |
| Huang, J; Ma, J; Mu, X; Qin, Y; Wu, G; Xu, S; Yang, K; Zhang, Z; Zhou, H | 1 |
| Ahuja, AT; Chan, ATC; Chan, SL; Hui, EP; Kam, MKM; King, AD; Loong, HH; Ma, BBY; Mo, F; Zee, BCY | 1 |
| Deutsch, E; Soria, JC | 1 |
| Cai, Z; Chen, W; Jin, Q; Ye, X | 1 |
2 trial(s) available for pyrroles and Nasopharyngeal Carcinoma
| Article | Year |
|---|---|
Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Humans; Indoles; Male; Middle Aged; Nasopharyngeal Carcinoma; Pyrroles; Receptor Protein-Tyrosine Kinases | 2018 |
Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Chemoradiotherapy; Epistaxis; Female; Hematemesis; Hemoptysis; Humans; Indoles; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Treatment Outcome | 2011 |
4 other study(ies) available for pyrroles and Nasopharyngeal Carcinoma
| Article | Year |
|---|---|
Sunitinib Induces NK-κB-dependent NKG2D Ligand Expression in Nasopharyngeal Carcinoma and Hepatoma Cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Carcinoma, Hepatocellular; Coculture Techniques; Combined Modality Therapy; Cytotoxicity, Immunologic; Gene Expression; Hep G2 Cells; Humans; Immunologic Surveillance; Immunotherapy, Adoptive; Indoles; Killer Cells, Natural; Ligands; Liver Neoplasms; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; NF-kappa B; NK Cell Lectin-Like Receptor Subfamily K; Protein Kinase Inhibitors; Pyrroles; RNA, Small Interfering; Signal Transduction; Sunitinib | 2017 |
Famitinib enhances nasopharyngeal cancer cell radiosensitivity by attenuating radiation-induced phosphorylation of platelet-derived growth factor receptor and c-kit and inhibiting microvessel formation.
Topics: Animals; Carcinoma; Cell Line, Tumor; Female; Humans; Indoles; Mice; Mice, Nude; Microvessels; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neovascularization, Pathologic; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Radiation Tolerance; Receptor, Platelet-Derived Growth Factor beta; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2015 |
Hemorrhage caused by antiangiogenic therapy within previously irradiated areas: expected consequence of tumor shrinkage or a warning for antiangiogenic agents combined to radiotherapy?
Topics: Antineoplastic Agents; Carcinoma; Female; Hematemesis; Hemoptysis; Humans; Indoles; Male; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Pyrroles; Sunitinib | 2011 |
[The effect and mechanism of SU11248 on proliferation of nasopharyngeal carcinoma cell line CNE-2].
Topics: Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cyclin G1; Cyclin-Dependent Kinase Inhibitor p27; Gene Expression Regulation, Neoplastic; Humans; Indoles; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Pyrroles; RNA, Messenger; Sunitinib | 2013 |